<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">841248</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2022.841248</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>miR-654-5p Contributes to the Activation and Proliferation of Hepatic Stellate Cells by Targeting RXR&#x3b1;</article-title>
<alt-title alt-title-type="left-running-head">Ma et al.</alt-title>
<alt-title alt-title-type="right-running-head">MiR-654-5p Targets RXR&#x3b1; in HSCs</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Heming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1590386/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xiaomei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1388249/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gao</surname>
<given-names>Xiuzhu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1569259/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Niu</surname>
<given-names>Junqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1507848/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Hepatology</institution>, <institution>The First Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education</institution>, <institution>The First Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/602805/overview">Xiaodong Zhao</ext-link>, Shanghai Jiao Tong University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/968162/overview">Liya Pi</ext-link>, Tulane University, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/674633/overview">Zheng Jin</ext-link>, Shenzhen University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Xiuzhu Gao, <email>xiuzhugao@jlu.edu.cn</email>; Junqi Niu, <email>junqiniu@jlu.edu.cn</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Signaling, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>841248</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>12</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>03</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Ma, Wang, Liu, Wang, Gao and Niu.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Ma, Wang, Liu, Wang, Gao and Niu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Liver fibrosis (LF) is a major disease that threatens human health. Hepatic stellate cells (HSCs) contribute directly to LF via extracellular matrix (ECM) secretion. Moreover, RXR&#x3b1; is an important nuclear receptor that plays a key regulatory role in HSC activation. Meanwhile, microRNAs (miRNAs) have been identified as significant regulators of LF development. In particular, miR-654-5p is involved in cellular migration and proliferation, and <italic>via</italic> bioinformatics analysis, has been identified as a potential factor that targets RXR&#x3b1; in humans and in mice. However, the precise relationship between miR-654-5p and RXR&#x3b1; in the context of LF, remains unknown and is the primary focus of the current study. To establish <italic>in vitro</italic> activated cell model human primary HSCs were cultured <italic>in vitro</italic> and LX-2 cells were stimulated with recombinant human TGF-&#x3b2;1. mRNA and protein levels of RXR&#x3b1;, miR-654-5p and fibrogenic genes were compared in quiescent and activated HSCs. Moreover, after transfected with miR-654-5p mimics, the expression changes of above related genes in LX-2 cells were estimated. Meanwhile, cell proliferation and apoptosis were detected in miR-654-5p overexpressed LX-2 cells. Simultaneously, the targeted binding between miR-654-5p and RXR&#x3b1; was verified in LX-2 cells. Carbon tetrachloride (CCl<sub>4</sub>)-induced mouse model with liver fibrosis was use to research the role of the miR-654-5p <italic>in vitro</italic>. Our results show that miR-654-5p expression levels increased in activated human HSCs and TGF&#x3b2;-treated LX-2 cells. Moreover, miR-654-5p mimics markedly promoted LX-2 cell proliferation while inhibiting their apoptosis. Accordingly, the expression levels of RXR&#x3b1; are decreased in activated HSCs and LX-2 cells. Additionally, dual-luciferase reporter assay results reveal direct targeting of RXR&#x3b1; by miR-654-5p. Similarly, <italic>in vivo</italic> miR-654-5p overexpression aggravates LF in mice that are intraperitoneally injected with CCl<sub>4</sub>. Taken together, our findings elucidated a novel molecular mechanism with potential use for treatment of LF.</p>
</abstract>
<kwd-group>
<kwd>RXR&#x3b1;</kwd>
<kwd>miR-654-5p</kwd>
<kwd>hepatic stellate cells</kwd>
<kwd>liver fibrosis</kwd>
<kwd>target</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Liver fibrosis (LF) is a dynamic and reversible pathological process. Uncontrolled LF progresses to cirrhosis and even hepatocellular carcinoma (HCC), a major disease threatening human health (<xref ref-type="bibr" rid="B30">Tao et al., 2020</xref>). LF is characterized by extracellular matrix (ECM) accumulation, a process that is closely associated with hepatic stellate cells (HSCs). Transdifferentiation of quiescent HSCs into a myofibroblast-like cells is referred to as &#x201c;activation&#x201d; (<xref ref-type="bibr" rid="B32">Tsuchida and Friedman, 2017</xref>). In fibrotic livers, activated HSCs can proliferate, migrate, and contract, while also secreting a large amount of ECM, tissue inhibitors of metalloproteinases (TIMPs), and matrix metalloproteinases (MMPs), all of which play key roles in LF (<xref ref-type="bibr" rid="B7">Ezhilarasan et al., 2018</xref>; <xref ref-type="bibr" rid="B27">Roeb, 2018</xref>). Hence, maintenance of HSC quiescence may serve to resolve LF.</p>
<p>MicroRNAs (miRNAs) are &#x223c;22&#xa0;nt long, single-stranded small non-coding RNAs that regulate various cellular biological processes, including cell proliferation, apoptosis, and differentiation (<xref ref-type="bibr" rid="B31">Tsai and Yu, 2010</xref>). As such have summarized several miRNAs involved in the regulation of LF through HSCs (<xref ref-type="bibr" rid="B6">Ezhilarasan, 2020</xref>; <xref ref-type="bibr" rid="B8">Fang et al., 2021</xref>). In particular, microRNA-654-5p (miR-654-5p) is involved in autophagy and inflammatory signaling pathways (<xref ref-type="bibr" rid="B14">Kong, 2020</xref>; <xref ref-type="bibr" rid="B18">Li et al., 2021a</xref>; <xref ref-type="bibr" rid="B34">Wang et al., 2021</xref>) and regulates the proliferation and migration of various tumor cells (<xref ref-type="bibr" rid="B29">Tan et al., 2016</xref>; <xref ref-type="bibr" rid="B21">Lu et al., 2018</xref>; <xref ref-type="bibr" rid="B12">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="B38">Xu et al., 2020</xref>; <xref ref-type="bibr" rid="B39">Zhang et al., 2020</xref>). Meanwhile, inhibition of the miR-654-5p/SMAD2 axis induces HCC cell proliferation, invasion, and migratio (<xref ref-type="bibr" rid="B22">Lu et al., 2021</xref>). However, the role of miR-654-5p in HSC activation within the context of LF, as well as the underlying potential molecular mechanism remain to be elucidated.</p>
<p>Retinoic acid (RA), the main active metabolite of vitamin A, has a key role in several essential biological processes, including embryogenesis, organogenesis, cell proliferation, differentiation, and apoptosis. The biological effects of RA are primarily mediated by retinoid receptors (RRs), including retinoid acid receptors (RARs) and retinoid X receptors (RXRs). RRs regulate gene transcription after binding to retinoic acid response elements (RAREs) in the target gene promoter region (<xref ref-type="bibr" rid="B1">Abdel-Bakky et al., 2020</xref>; <xref ref-type="bibr" rid="B15">Li et al., 2021b</xref>). RRs are expressed in quiescent HSCs in rodents and humans. RXRs have three subtypes: RXR-&#x3b1;, -&#x3b2;, and -&#x3b3;, of which RXR&#x3b1; is the most expressed subtype on HSCs. However, the expression of RXR&#x3b1; decreases following HSC activation (<xref ref-type="bibr" rid="B33">Vogel et al., 2000</xref>). Specifically, bioinformatics analysis demonstrated that RXR&#x3b1; expression is downregulated in the livers of patients with liver cirrhosis caused by hepatitis B virus (HBV), hepatitis C virus, and nonalcoholic fatty liver disease (NAFLD), and is also downregulated in HSCs that are activated <italic>in vivo</italic> in carbon tetrachloride (CCl<sub>4</sub>)-induced LF mice (<xref ref-type="bibr" rid="B11">He et al., 2020</xref>). Consistent with this, downregulation of RXR&#x3b1; mRNA has also been reported during activation of HSCs in rats with advanced LF induced by bile duct ligation and CCl<sub>4</sub>. In contrast, overexpression of RXR&#x3b1; in HSCs <italic>in vitro</italic> can inhibit the secretion of &#x3b1;-smooth muscle actin (&#x3b1;-SMA) and collagen I in HSCs, while <italic>in vivo</italic> overexpression of RXR&#x3b1; could resolve LF in mice, suggesting that this nuclear receptor plays a key role in the activation of HSCs and in LF (<xref ref-type="bibr" rid="B25">Ohata et al., 1997</xref>; <xref ref-type="bibr" rid="B35">Wang et al., 2011</xref>). Indeed, our previous RNA-seq study reported that miR-654-5p expression is significantly upregulated, while RXR&#x3b1; expression is downregulated in culture-activated human primary HSCs <italic>in vitro</italic> (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>). Therefore, in the current study, we hypothesized that miR-654-5p participates in the activation and proliferation of HSCs through the negative regulation of RXR&#x3b1;, thereby promoting LF.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Isolation of Primary Human HSCs, Cell Culture and Stimulation</title>
<p>Liver tissues were obtained intraoperatively from patients undergoing orthotopic liver transplantation or surgical liver resection for primary biliary cirrhosis, primary sclerosing cholangitis, and HBV-related cirrhosis. Demographic and clinical characteristics, laboratory indices, and disease statuses of the patients are shown in <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>. The distance from the obtained liver tissue to the edge of the lesion was at least 5&#xa0;cm. Written informed consent was obtained from the patients for use of their tissues for research purposes, according to the ethical guidelines of the First Hospital of Jilin University (NO. 2019-356). Subsequently, primary human HSCs were isolated from the wedge sections of human livers using the density gradient centrifugation method (<xref ref-type="bibr" rid="B36">Werner et al., 2015</xref>). In brief, collagenase IV (Sigma-Aldrich, St. Louis, MO, United States) was used to perfuse and digest the liver tissue, and a hepatic cell suspension was obtained after blunt separation. Primary hepatocytes (HCs) were separated after centrifugation at 50&#xa0;<italic>g</italic> for 5&#xa0;min, and the supernatant was further centrifuged at 500&#xa0;g for 5&#xa0;min at 4&#xb0;C. Using 8.5% Optiprep gradient medium (Stemcell, Vancouver, Canada), we removed other non-parenchymal cells, including liver sinusoidal endothelial cells and Kupffer cells. Primary HSCs, and the human immortalized hepatic stellate cell line (LX-2) (kindly provided by Dr. Zhengkun Tu) were maintained in Dulbecco&#x2019;s modified eagle&#x2019;s medium (DMEM; Gibco, Waltham, MA, United States) supplemented with 10% fetal bovine serum (FBS; Gibco). For TGF&#x3b2;1-induced activation, LX-2 cells were treated with TGF-&#x3b2;1 (5&#xa0;ng/&#x3bc;L; R&#x26;D, United States) for 24&#xa0;h after starvation. The cells were then incubated in a 5% CO<sub>2</sub> incubator at 37&#xb0;C.</p>
</sec>
<sec id="s2-2">
<title>Immunofluorescence Staining</title>
<p>HSCs were fixed with 4% paraformaldehyde (Solarbio, Beijing, China) for 15&#xa0;min at room temperature (25&#xb0;C), washed with phosphate-buffered saline (PBS), and subsequently blocked with 2% bovine serum albumin for 30&#xa0;min. HSCs were then incubated for 2&#xa0;h at 37&#xb0;C with a primary monoclonal anti-&#x3b1;-SMA antibody (1:200 dilution; Abcam, Cambridge, MA). After washing with PBS, the cells were incubated for 1&#xa0;h at room temperature with a secondary polyclonal goat anti-rabbit IgG (H &#x2b; L; 1:200; Earthox, San Francisco, United States). The negative control was obtained by not using the primary antibodies. After incubation with the above antibodies, cells were washed with PBS and counterstained with 4,6-diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA, United States) for 3&#xa0;min. Immunofluorescence staining was detected and photographed using a laser scanning microscope (Axiovert 100M; Zeiss, Jena, Germany) at 200&#xd7; magnification.</p>
</sec>
<sec id="s2-3">
<title>Histological Analyses</title>
<p>Mouse liver tissue sections were cut into 3&#xa0;&#x3bc;m silces, and embedded in paraffin. Collagen deposition in liver tissue sections was localized using standard histological techniques with Masson&#x2019;s trichrome staining. Each section was assessed under a light microscopic and photographed at 40&#xd7; magnification.</p>
</sec>
<sec id="s2-4">
<title>Animals</title>
<p>Male C57BL/6 mice (6&#xa0;weeks old) were purchased from Charles River (Beijing, China). All mice were fed a standard rat chow diet and housed under a 12&#xa0;h light/dark cycle. After acclimatization for 7&#xa0;days, the mice were randomly divided into four groups: negative control (NC; n &#x3d; 6), CCl<sub>4</sub> group (n &#x3d; 6), CCl<sub>4</sub>&#x2b;AAV-NC group (n &#x3d; 7), and CCl<sub>4</sub>&#x2b;AAV-miR-654-5p group (n &#x3d; 7). Adeno-associated virus serotype 8 (AAV8) particles encoding miR-654-5p (hereafter referred to as AAV- miR-654-5p) and control AAV particles (AAV-NC) were purchased from Hanbio, Shanghai, China, and were administered to the CCl4&#x2b;AAV-miR-654-5p and CCl4&#x2b;AAV-NC groups at a dose of 3 &#xd7; 10<sup>11</sup> viral genomes (vg) per animal <italic>via</italic> tail vein injection. After 1&#xa0;week, the mice in the CCl<sub>4</sub>, CCl<sub>4</sub>&#x2b;AAV-NC, and CCl<sub>4</sub>&#x2b;AAV-miR-654-5p groups were intraperitoneally injected with a 10% CCl4 (Aladdin, China) dose at 1&#xa0;ml/kg (diluted with edible olive oil before injection) three times per week. Mice in the NC group were similarly administered the same solvent. After 6&#xa0;weeks, the mice were sacrificed, and their liver tissues were dissected. Blood samples were centrifuged, and serum was stored at &#x2212;80&#xb0;C. Additionally, a portion of the liver tissue samples were fixed in 4% formaldehyde, while the remaining sample was stored at &#x2212;80&#xb0;C until use. All experiments involving mice were conducted in accordance with the ethical guidelines of the Animal Ethics Committee of First Hospital of Jilin University (Approval NO. 20220002).</p>
</sec>
<sec id="s2-5">
<title>Transient Transfection</title>
<p>Cells were transfected with 50&#xa0;nM miR-654-5p mimics or mimics-NC (RiboBio, Guangzhou, China) using Lipofectamine 3,000 (Invitrogen) following the manufacturer&#x2019;s protocol. Similarly, cells were transfected with pcDNA3.1-RXR&#x3b1; plasmid or its control plasmid pcDNA3.1-NC (Sangon Biotech).</p>
</sec>
<sec id="s2-6">
<title>Western Blot Assay</title>
<p>Cells were lysed in RIPA buffer (Beyotime, Shanghai, China) containing PMSF (Solarbio). This assay was performed using standard western blotting techniques with the following primary antibodies: anti-RXR&#x3b1; (Abcam), anti-collagen I (Proteintech, Chicago, United States), anti-MMP2 (Proteintech) and anti-tubulin (YTHX Biotechnology, Beijing, China).</p>
</sec>
<sec id="s2-7">
<title>Quantitative Reverse&#x2010;transcription Polymerase Chain Reaction (qRT-PCR)</title>
<p>Total RNA was extracted from the cells/liver tissues using Eastep&#x2122; Total RNA Extraction Kit (Promega, Madison, United States) and miRNAs were extracted from the cells/liver tissues using the EasyPure miRNA Kit (TransGen, Beijing, China) following the manufacturer&#x2019;s instructions. Complementary DNA (cDNA) was synthesized using TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix (TransGen) to detect mRNA. cDNA was generated using a Ribo SCRIPT&#x2122; Reverse Transcription kit (RiboBio) to detect miRNA. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using PerfectStart&#x2122; Green qPCR SuperMix (TransGen). &#x3b2;-actin was used as an mRNA control. U6 was used as a reference miRNA control. The primers for U6/miR-654-5p were obtained from RiboBio Co., Ltd. All other qPCR primers used are listed in <xref ref-type="table" rid="T1">Table 1</xref> qPCR was performed using the Agilent Mx3005P Real-Time PCR System (Applied Biosystems, Foster City, CA).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Primers used for the real&#x2010;time polymerase chain reaction.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Genes</th>
<th align="center">Forward (5&#x2032;-3&#x2032;)</th>
<th align="center">Reverse (5&#x2032;-3&#x2032;)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">has-&#x3b2;-actin</td>
<td>CAC&#x200b;CAT&#x200b;TGG&#x200b;CAA&#x200b;TGA&#x200b;GCG&#x200b;GTT&#x200b;C</td>
<td>AGG&#x200b;TCT&#x200b;TTG&#x200b;CGG&#x200b;ATG&#x200b;TCC&#x200b;ACG&#x200b;T</td>
</tr>
<tr>
<td align="left">has-col1&#x3b1;1</td>
<td>GAG&#x200b;GGC&#x200b;CAA&#x200b;GAC&#x200b;GAA&#x200b;GAC&#x200b;ATC</td>
<td>CAG&#x200b;ATC&#x200b;ACG&#x200b;TCA&#x200b;TCG&#x200b;CAC&#x200b;AAC</td>
</tr>
<tr>
<td align="left">has-MMP2</td>
<td>AGC&#x200b;GAG&#x200b;TGG&#x200b;ATG&#x200b;CCG&#x200b;CCT&#x200b;TTA&#x200b;A</td>
<td>CAT&#x200b;TCC&#x200b;AGG&#x200b;CAT&#x200b;CTG&#x200b;CGA&#x200b;TGA&#x200b;G</td>
</tr>
<tr>
<td align="left">has-&#x3b1;-SMA</td>
<td>CTA&#x200b;TGC&#x200b;CTC&#x200b;TGG&#x200b;ACG&#x200b;CAC&#x200b;AAC&#x200b;T</td>
<td>CAG&#x200b;ATC&#x200b;CAG&#x200b;ACG&#x200b;CAT&#x200b;GAT&#x200b;GGC&#x200b;A</td>
</tr>
<tr>
<td align="left">has-RXR&#x3b1;</td>
<td>TTG&#x200b;CCA&#x200b;AGC&#x200b;AGC&#x200b;CGA&#x200b;CAA&#x200b;ACA&#x200b;G</td>
<td>AAG&#x200b;GAG&#x200b;GCG&#x200b;ATG&#x200b;AGC&#x200b;AGC&#x200b;TCA&#x200b;T</td>
</tr>
<tr>
<td align="left">mmu-col1&#x3b1;1</td>
<td>CCT&#x200b;CAG&#x200b;GGT&#x200b;ATT&#x200b;GCT&#x200b;GGA&#x200b;CAA&#x200b;C</td>
<td>CAG&#x200b;AAG&#x200b;GAC&#x200b;CTT&#x200b;GTT&#x200b;TGC&#x200b;CAG&#x200b;G</td>
</tr>
<tr>
<td align="left">mmu-&#x3b1;-SMA</td>
<td>TGC&#x200b;TGA&#x200b;CAG&#x200b;AGG&#x200b;CAC&#x200b;CAC&#x200b;TGA&#x200b;A</td>
<td>CAG&#x200b;TTG&#x200b;TAC&#x200b;GTC&#x200b;CAG&#x200b;AGG&#x200b;CAT&#x200b;AG</td>
</tr>
<tr>
<td align="left">mmu-MMP2</td>
<td>CAA&#x200b;GGA&#x200b;TGG&#x200b;ACT&#x200b;CCT&#x200b;GGC&#x200b;ACA&#x200b;T</td>
<td>TAC&#x200b;TCG&#x200b;CCA&#x200b;TCA&#x200b;GCG&#x200b;TTC&#x200b;CCA&#x200b;T</td>
</tr>
<tr>
<td align="left">mmu-RXR&#x3b1;</td>
<td>GTG&#x200b;AAA&#x200b;GAT&#x200b;GGG&#x200b;ATT&#x200b;CTC&#x200b;CTG&#x200b;GC</td>
<td>GTC&#x200b;ACG&#x200b;CAT&#x200b;CTT&#x200b;AGA&#x200b;CAC&#x200b;CAG&#x200b;C</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-8">
<title>Luciferase Reporter Assay</title>
<p>The wild-type (WT) or mutant (MUT) RXR&#x3b1; 3&#x2b9; UTR was synthesized and subcloned into the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega). HEK293 cells were co-transfected with miR-654-5p mimics and pGLO&#x2010;WT&#x2010;RXR&#x3b1; or pGLO&#x2010;MUT&#x2010;RXR&#x3b1; using Lipofectamine 3,000. Luciferase activity was measured 48&#xa0;h after the co-transfection using the Dual-Luciferase Reporter Assay System (Promega) following the manufacturer&#x2019;s instructions. Relative luciferase activity was calculated by normalizing firefly luciferase activity to Renilla luciferase activity.</p>
</sec>
<sec id="s2-9">
<title>Cell Counting Kit-8 (CCK-8) Assay</title>
<p>LX-2 cells were seeded into 96-well plates (3,000 cells/well) and cultured in serum-free DMEM after transfection; the medium was replaced every 48&#xa0;h. CCK-8 solution (10 uL; Beyotime, Shanghai, China) was added to each well at 24, 48, 72, 96, 120, 144, and 168&#xa0;h after transfection, respectively. Absorbance was measured at 450&#xa0;nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, United States).</p>
</sec>
<sec id="s2-10">
<title>Flow Cytometry Analysis</title>
<p>To detect cell apoptosis, LX-2 cells were cultured in serum-free DMEM for 5&#xa0;days after transfection to induce apoptosis by starvation. Trypsin was used to digest the cells for flow cytometry analysis. Cell apoptosis was measured by staining cells with PE Annexin V and 7-AAD using a PE Annexin V Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, NJ, United States) for 15&#xa0;min at room temperature in the dark. Apoptosis was detected using a FACS Canto flow cytometer (BD).</p>
<p>To detect the purity of isolated HSCs, freshly isolated HSCs were washed and counted They were then incubated with CD68 and CD146 antibodies (BD Biosciences, San Jose, CA) in the dark at room temperature for 30&#xa0;min. In addition, other HSCs were cultured <italic>in vitro</italic> for 14&#xa0;days and then collected. After washing, cells were fixed and permeabilized with the BD Cytofix/Cytoperm&#x2122; Fixation/Permeabilization kit (BD) according to the manufacturer&#x2019;s introductions. Fixed cells were further incubated with an &#x3b1;-SMA antibody (R&#x26;D). After washing, labeled cells were resuspended and analyzed by flow cytometry. Flowjo was used to analyze the flow data.</p>
</sec>
<sec id="s2-11">
<title>ALT, AST and Hydroxyproline Measurements</title>
<p>The levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and hydroxyproline (Hyp) were measured in the mice using ALT, AST and Hyp measuring reagent kits (Nanjingjiancheng, Nanjing, China) according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2-12">
<title>Statistical Analysis</title>
<p>Data are presented as mean &#xb1; standard deviation (SD) of at least three independent experiments. The paired <italic>t</italic>-test was used to analyze the differences in mRNA or miRNA expression from qRT-PCR results, and &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001, and &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0001 from Prism 8.0.1 software (GraphPad Software, San Diego, CA) were defined as statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Identification of Isolated HSCs</title>
<p>Although there are no known specific markers for quiescent human HSCs, these cells store several cytoplasmic retinoid droplets rich in vitamin A. Therefore, we detected spontaneous fluorescence of these lipid droplets in freshly separated (1&#xa0;d) HSCs. HSCs were cultured in plastic dishes for 14&#xa0;days to induce spontaneous cellular activation. The activated HSCs underwent morphological changes and expressed &#x3b1;-SMA (<xref ref-type="fig" rid="F1">Figures 1A,B</xref>). Moreover, since HSCs are similar in size to liver endothelial cells and macrophages, it is likely that the layer obtained following density gradient centrifugation contained all three of these cell subsets. Therefore, we identified liver endothelial cells <italic>via</italic> CD146 and macrophages <italic>via</italic> CD68. The remaining CD68<sup>&#x2013;</sup> CD146<sup>&#x2013;</sup> cells were considered to be HSCs. The results showed that the purity of freshly isolated HSCs was &#x3e;90% (<xref ref-type="fig" rid="F1">Figure 1C</xref>). Subsequently, we labeled HSCs with &#x3b1;-SMA and analyzed them <italic>via</italic> flow cytometry, confirming that the purity of isolated HSCs was &#x3e;90% (<xref ref-type="fig" rid="F1">Figure 1D</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Identification of primary human HSCs isolated from liver tissue specimens. <bold>(A)</bold> Freshly isolated primary HSCs (1&#xa0;d) and HSCs cultured <italic>in vitro</italic> for 14&#xa0;days in a light microscopic field at 200&#xd7; magnification. <bold>(B)</bold> Spontaneous fluorescence (green) and DAPI (blue) staining under a laser scanning microscope in a light microscopic field (upper panels, original magnification: &#xd7;200), and immunofluorescence staining with an anti-&#x3b1;-SMA antibody (red) and DAPI (blue; lower panels, original magnification: &#xd7;200). <bold>(C)</bold> Purity of freshly isolated human HSCs determined by flow cytometry. CD146 identifies liver endothelial cells, and CD68 identifies macrophages. Cells that express neither CD68 nor CD146 are considered HSCs <bold>(D)</bold> Purity of culture-induced activated HSCs determined by flow cytometry. HSCs, hepatic stellate cells.</p>
</caption>
<graphic xlink:href="fcell-10-841248-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>MiR-654-5p is Significantly Upregulated While RXR&#x3b1; is Downregulated During Natural Activation of HSCs and in TGF-&#x3b2;1-Treated LX-2 Cells</title>
<p>To confirm the spontaneous activation of HSCs following <italic>in vitro</italic> culture, the expression levels of activation-related genes in HSCs were measured. After 14&#xa0;days of <italic>in vitro</italic> culture, the mRNA expression levels of collagen type 1-&#x3b1;1 (col1&#x3b1;1), &#x3b1;-SMA, and matrix metalloproteinase 2 (MMP2) were significantly upregulated compared to those at on day 1 (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Similarly, after 48&#xa0;h of TGF&#x3b2;1 stimulation, the mRNA expression levels of col1&#x3b1;1 and MMP2 in LX-2 cells were significantly upregulated, while that of &#x3b1;-SMA decreased (<xref ref-type="fig" rid="F2">Figure 2B</xref>). After <italic>in vitro</italic> culturing for 14&#xa0;days, miR-654-5p and RXR&#x3b1; expression was evaluated in activated primary HSCs. Our results showed that the relative expression of miR-654-5p was significantly increased in activated HSCs compared to quiescent HSCs (freshly isolated; p &#x3c; 0.05), while the relative expression of RXR&#x3b1; decreased (<italic>p</italic> &#x3c; 0.001; <xref ref-type="fig" rid="F2">Figure 2C</xref>). In addition, we treated LX-2 cells with TGF-&#x3b2;1, an HSCs activator. A similar trend was observed in TGF-&#x3b2;-induced LX-2 cells compared to the NC group (<italic>p</italic> &#x3c; 0.05 and <italic>p</italic> &#x3c; 0.001, respectively; <xref ref-type="fig" rid="F2">Figure 2D</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>MiR-654-5p expression levels increase while RXR&#x3b1; mRNA expression levels decrease in culture-activated HSCs and TGF&#x3b2;1-treated LX-2 cells. <bold>(A)</bold> col1&#x3b1;1, &#x3b1;-SMA, and MMP2 mRNA expression levels in culture-activated HSCs versus quiescent HSCs. Quantitative polymerase chain reaction analyses were performed to quantify mRNA expression levels with &#x3b2;-actin as a loading control <bold>(B)</bold> col1&#x3b1;1, &#x3b1;-SMA, and MMP2 mRNA expression levels in TGF&#x3b2;1-treated LX-2 cells versus the control group. <bold>(C)</bold> MiRNA-654-5p and RXR&#x3b1; expression levels in culture-activated HSCs versus quiescent HSCs. Quantitative polymerase chain reaction analyses were performed to quantify miRNA expression levels with U6 as a loading control <bold>(D)</bold> MiRNA-654-5p and RXR&#x3b1; expression levels in TGF&#x3b2;1-treated LX-2 cells versus in the control group. Error bars represent mean &#xb1; SEM of at least three experiments. &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001 and &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0001. HSCs, hepatic stellate cells.</p>
</caption>
<graphic xlink:href="fcell-10-841248-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Upregulation of miR-654-5p Promotes Activation and Proliferation of LX-2 Cells While Inhibiting Their Apoptosis</title>
<p>To explore the function of miR&#x2010;654&#x2010;5p in LF, we modulated the expression of miR&#x2010;654&#x2010;5p by transfecting LX-2 cells with mimics. First, we overexpressed miR&#x2010;654&#x2010;5p in LX-2 cells by transfection with miR-654-5p mimics (<xref ref-type="fig" rid="F3">Figure 3A</xref>) and found that overexpression of miR&#x2010;654&#x2010;5p promoted the mRNA expression levels of HSC activation markers col1&#x3b1;1 and MMP2 compared to the control group (mimics-NC; <xref ref-type="fig" rid="F3">Figure 3B</xref>; <italic>p</italic> &#x3c; 0.01 and <italic>p</italic> &#x3c; 0.05). Subsequently, LX-2 cells were treated with TGF&#x3b2;1 after miR-654-5p mimics/mimics-NC transfection. The resulting expression levels of col1&#x3b1;1 and MMP2 proteins were increased in miR-654-5p-overexpressing LX-2 cells (<xref ref-type="fig" rid="F3">Figure 3C</xref>). These results validated the functional relevance of miR&#x2010;654&#x2010;5p in the activation of HSCs <italic>in vitro</italic>.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Upregulation of miR-654-5p expression promotes activation and proliferation of LX-2 cells while inhibiting their apoptosis. <bold>(A)</bold> MiRNA-654-5p expression levels in LX-2 cells transfected with miR-654-5p mimics versus LX-2 cells transfected with mimics-NC <bold>(B)</bold> col1&#x3b1;1 and MMP2 mRNA expression levels in miR-654-5p overexpressing LX-2 cells versus the control group. <bold>(C)</bold> Expression of col1&#x3b1;1 and MMP2 protein in miR-654-5p overexpressing LX-2 cells versus in control group <bold>(D)</bold> Quantity and morphology of LX-2 cells transfected with mimics-NC and LX-2 cells transfected with the miR-654-5p mimic (cells were photographed under light microscopic field, 40&#xd7; magnification). <bold>(E)</bold> Effects of miR&#x2010;654&#x2010;5p mimics on the growth of LX-2 cells. Cells were transfected with the hsa&#x2010;miR&#x2010;654&#x2010;5p mimics. CCK-8 assay evaluated cell survival <bold>(F)</bold> Effects of the hsa&#x2010;miR&#x2010;654&#x2010;5p mimics on apoptosis of LX-2 cells <bold>(G)</bold> Flow cytometric analysis of apoptotic cells ratio. Cells were transfected with the hsa&#x2010;miR&#x2010;654&#x2010;5p mimics and cultured in an FBS-free medium for 5&#xa0;days. Error bars represent mean &#xb1; SEM of at least three independent experiments. &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001; NS, <italic>p</italic> &#x3e; 0.05.</p>
</caption>
<graphic xlink:href="fcell-10-841248-g003.tif"/>
</fig>
<p>LX-2 cells transfected with the miR-654-5p mimic were then starved in an FBS-free medium for 5&#xa0;days. The resulting quantity and morphology of LX-2 cells differed from those of the NC group (<xref ref-type="fig" rid="F3">Figure 3D</xref>). Moreover, the CCK&#x2010;8 assay results showed that overexpression of miR&#x2010;654&#x2010;5p significantly promoted the proliferation of LX-2 cells (<xref ref-type="fig" rid="F3">Figure 3E</xref>).</p>
<p>In addition, flow cytometry analysis results suggested that LX-2 cells treated with the miR&#x2010;654&#x2010;5p mimic exhibited changes in apoptosis compared to mimic-NC. Specifically, three repeated experiments showed that Annexin V-positive cells were significantly increased after miR-654-5p transfection; therefore, miR-654-5p reduced early apoptosis of LX-2 cells (<xref ref-type="fig" rid="F3">Figures 3F,G</xref>). Overall, these results indicate that upregulation of miR&#x2010;654&#x2010;5p promotes the activation and proliferation of HSCs while inhibiting apoptosis.</p>
</sec>
<sec id="s3-4">
<title>MiR-654-5p Directly Targets RXR&#x3b1;</title>
<p>To identify the potential mRNAs targeted by miR-654-5p, bioinformatics analysis using TargetScan (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/vert_71/">http://www.targetscan.org/vert_71/</ext-link>) and miRwalk (<ext-link ext-link-type="uri" xlink:href="http://mirwalk.umm.uni-heidelberg.de/">http://mirwalk.umm.uni-heidelberg.de/</ext-link>) databases were carried out. Based on our lab RNA-seq data from the previous period, RXR&#x3b1; was noted to be a candidate involved in miR&#x2010;654&#x2010;5p regulation of HSCs. The speculative binding region between hsa&#x2010;miR&#x2010;654&#x2010;5p and RXR&#x3b1;, based on TargetScan results, is shown in <xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>. A dual-luciferase reporter assay was then used to validate the association between the two. To this end, luciferase reporter plasmids of WT&#x2010;RXR&#x3b1;- and MUT&#x2010;RXR&#x3b1; 3&#x2b9; UTR were constructed and are shown in <xref ref-type="fig" rid="F4">Figure 4A</xref>. Co-transfection of the luciferase reporter plasmid containing WT&#x2010;RXR&#x3b1; with miR&#x2010;654&#x2010;5p mimics in HEK&#x2010;293T cells decreased reporter activity. Conversely, the luciferase reporter plasmid co-transfection containing MUT&#x2010;RXR&#x3b1; with miR&#x2010;654&#x2010;5p mimics did not alter the luciferase activity (<xref ref-type="fig" rid="F4">Figure 4B</xref>). In addition, the levels of both RXR&#x3b1; mRNA and protein were markedly inhibited by miR&#x2010;654&#x2010;5p upregulation in LX-2 cells (<xref ref-type="fig" rid="F4">Figure 4C</xref>). These findings indicate that miR-654-5p directly targets RXR&#x3b1;.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>RXR&#x3b1; serves as a direct target of hsa&#x2010;miR&#x2010;654&#x2010;5p. <bold>(A)</bold> Binding region between hsa&#x2010;miR&#x2010;654&#x2010;5p and RXR&#x3b1;, and the luciferase reporter constructs containing the WT-RXR&#x3b1; or MUT-RXR&#x3b1; sequence <bold>(B)</bold> WT-RXR&#x3b1; or MUT-RXR&#x3b1; were co-transfected into HEK-293T cells with the hsa&#x2010;miR&#x2010;654&#x2010;5p mimic or the corresponding negative control <bold>(C)</bold> RXR&#x3b1; mRNA and protein expression levels in LX-2 cells. Grey values are measured through ImageJ. Cells were transfected with the hsa&#x2010;miR&#x2010;654&#x2010;5p mimic or their corresponding negative controls. Error bars represent mean &#xb1; SEM of at least three independent experiments. &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001; ns, <italic>p</italic> &#x3e; 0.05. MUT, mutant; WT, wild type.</p>
</caption>
<graphic xlink:href="fcell-10-841248-g004.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>RXR&#x3b1; Overexpression Rescues the Effect of miR&#x2010;654&#x2010;5p on LX-2 Cells</title>
<p>To verify that miR-654-5p regulates the activation, proliferation and apoptosis of HSCs by targeting RXR&#x3b1;, we transfected LX-2 cells with pcDNA3.1-RXR&#x3b1; plasmid to ectopically overexpress RXR&#x3b1; and confirmed the elevated levels of RXR&#x3b1; (<xref ref-type="fig" rid="F5">Figure 5A</xref>), LX-2 cells were then co-transfected with miR-654-5p mimics and pcDNA3.1-RXR&#x3b1;/pcDNA3.1-NC. Subsequently, the transfected cells were treated with TGF&#x3b2;1 to induce col1&#x3b1;1 expression. The results of western blotting showed that the overexpression of RXR&#x3b1; suppress the miR-654-5p mimics-induced expression of col1&#x3b1;1 protein (<xref ref-type="fig" rid="F5">Figure 5B</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>RXR&#x3b1; overexpression rescues the effect of miR&#x2010;654&#x2010;5p on LX-2 cells. <bold>(A)</bold> Expression level of RXR&#x3b1; protein in cells transfected with pcDNA3.1-RXR&#x3b1; plasmid or the corresponding negative control, grey values are measured through ImageJ <bold>(B)</bold> Expression level of col1&#x3b1;1 protein in LX-2 cells co-transfected with miR-654-5p mimics and pcDNA3.1-NC/pcDNA3.1-RXR&#x3b1; plasmid, grey values are measured through ImageJ. <bold>(C)</bold> Combined effects of the hsa&#x2010;miR&#x2010;654&#x2010;5p mimic and pcDNA3.1-NC/pcDNA3.1-RXR&#x3b1; on LX-2 cell apoptosis <bold>(D)</bold> Flow cytometric analysis to determine the ratio of apoptotic cells. After co-transfection with the hsa&#x2010;miR&#x2010;654&#x2010;5p mimic and pcDNA3.1-NC/pcDNA3.1-RXR&#x3b1;, cells were cultured in an FBS-free medium for 5&#xa0;days. <bold>(E)</bold> Cell proliferation evaluated via CCK-8 assay after co-transfection with the miR&#x2010;654&#x2010;5p mimic and pcDNA3.1-NC/pcDNA3.1- RXR&#x3b1;. Error bars represent mean &#xb1; SEM of at least three independent experiments. &#x2a;<italic>p</italic> &#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fcell-10-841248-g005.tif"/>
</fig>
<p>The co-transfected cells were also obtained to assess apoptosis using flow cytometry analysis. Results showed that following co-transfection with pcDNA3.1-RXR&#x3b1; and miR&#x2010;654&#x2010;5p mimics, the proportion of LX-2 cells undergoing early apoptosis had increased compared to those transfected with pcDNA3.1-NC and miR&#x2010;654&#x2010;5p mimics (<xref ref-type="fig" rid="F5">Figures 5C,D</xref>). Similarly, CCK-8 assay results showed a decline in the proliferation in cells co-transfected with pcDNA3.1-RXR&#x3b1; and miR&#x2010;654&#x2010;5p mimics (<xref ref-type="fig" rid="F5">Figure 5E</xref>).</p>
</sec>
<sec id="s3-6">
<title>MiR-654-5p Is Increased in CCl<sub>4</sub>-Induced LF, and miR-654-5p Overexpression Aggravates LF in Mice</title>
<p>To further investigate the role of miR-654-5p <italic>in vivo</italic>, we established a CCl<sub>4</sub>-induced LF mouse model. The mRNA levels of &#x3b1;-SMA, col1&#x3b1;1, and MMP2, were higher in the livers of CCl<sub>4</sub>-treated mice than in those of control mice (<xref ref-type="fig" rid="F6">Figure 6A</xref>). Masson&#x2019;s trichrome staining further revealed increased ECM deposition in the livers of CCl4-treated mice compared to those of control mice. In addition, Hyp content was upregulated in the liver tissues of mice treated with CCl<sub>4</sub> (<xref ref-type="fig" rid="F6">Figure 6B</xref>). These results confirmed that CCl<sub>4</sub> induced LF in the mouse model.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>MiR-654-5p expression level is increased causing an aggravating effect in CCl4-induced mouse LF, owing to RXR&#x3b1; targeting. <bold>(A)</bold> col1&#x3b1;1, &#x3b1;-SMA, and MMP2 mRNA expression levels in the livers of CCl<sub>4</sub>-treated mice versus vehicle. Quantitative polymerase chain reaction analyses were performed to quantify mRNA expression levels, with &#x3b2;-actin as a loading control <bold>(B)</bold> After treating with olive oil control (vehicle) or CCl4 for 6&#xa0;weeks, Masson&#x2019;s trichrome images (40&#xd7; magnification) and hydroxyproline measurement were used to evaluate liver fibrosis. <bold>(C)</bold> MiR-654-5p and RXR&#x3b1; levels in liver tissues. U6 was used as a loading control for miR-654-5p <bold>(D)</bold> Expression levels of miR-654-5p and RXR&#x3b1;, as quantified <italic>via</italic> qPCR analysis of liver tissue samples. <bold>(E)</bold> Serum ALT and AST levels quantified to determine the extent of liver damage in the different groups <bold>(F)</bold> Liver fibrosis evaluated <italic>via</italic> Masson&#x2019;s trichrome staining and hydroxyproline measurement. Error bars represent mean &#xb1; SEM of at least three in dependent experiments. &#x2a;<italic>p</italic> &#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001 and &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0001; ns, <italic>p</italic> &#x2265; 0.05. CCl<sub>4</sub>, carbon tetrachloride; ALT, alanine aminotransferase; AST, aspartate aminotransferase.</p>
</caption>
<graphic xlink:href="fcell-10-841248-g006.tif"/>
</fig>
<p>Subsequently, the levels of mmu-miR-654-5p and mmu-RXR&#x3b1; between the CCl<sub>4</sub> model and NC groups were estimated. Results showed that mmu-miR-654-5p expression was upregulated in fibrotic mouse, while mmu-RXR&#x3b1; mRNA level was consistently downregulated (<xref ref-type="fig" rid="F6">Figure 6C</xref>). The targeting relationship between mmu-miR-654-5p and mmu-RXR&#x3b1; was then predicted using TargetScan (<xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). To assess the delivery of AAV into the liver, the level of miR-654-5p was quantified in mouse livers by qRT-PCR analysis. Expression of miR-654-5p was significantly upregulated in the CCl<sub>4</sub>&#x2b;AAV-miR-654-5p group compared to that in the CCl<sub>4</sub>&#x2b;AAV-NC group. Consistent with this, the mRNA expression of RXR&#x3b1; was decreased (<xref ref-type="fig" rid="F6">Figure 6D</xref>). In addition, serum ALT and AST levels were compared between the CCl<sub>4</sub>&#x2b;AAV-miR-654-5p and CCL4&#x2b;AAV-NC groups. No significant differences were observed in AST and ALT content levels between the two groups (<xref ref-type="fig" rid="F6">Figure 6E</xref>). Finally, we also observed a significant increase in fibrosis within AAV-miR-654-5p overexpressing livers, as evidenced by increased collagen deposition in the liver, detected <italic>via</italic> Masson&#x2019;s trichrome staining, and increased Hyp levels (<xref ref-type="fig" rid="F6">Figure 6F</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In the current study, our findings showed that miR-654-5p expression was upregulated in culture-induced activated human primary HSCs and TGF-&#x3b2;1-stimulated LX-2 cells, suggesting that miR-654-5p is, at least partially, involved in LF development. Furthermore, transfection of cells with the miR-654-5p mimic significantly induced ECM synthesis, upregulated col1&#x3b1;1 expression, and promoted HSC proliferation, while inhibiting the apoptosis of HSCs. In addition, we found that miR-654-5p regulates profibrotic genes expression and cellular biological functions through RXR&#x3b1;.</p>
<p>LF is characterized by excessive deposition of ECM components, in particular type I collagen (<xref ref-type="bibr" rid="B4">Bataller and Brenner, 2005</xref>; <xref ref-type="bibr" rid="B9">Friedman, 2008</xref>). HSCs convert from a resting to active phenotype and migrate to the damaged area where they produce ECM after liver injury (<xref ref-type="bibr" rid="B32">Tsuchida and Friedman, 2017</xref>). Meanwhile, MMPs regulate liver matrix degradation, with MMP2 defined as one of the most relevant MMPs for degrading the normal liver matrix. Indeed, MMP2 is significantly upregulated in activated HSCs during liver fibrosis progression, regulating the degradation of the normal liver matrix and further promoting LF (<xref ref-type="bibr" rid="B2">Arthur, 2000</xref>). Col1&#x3b1;1 and MMP2 are primarily produced by HSCs during LF (<xref ref-type="bibr" rid="B3">Barcena-Varela et al., 2019</xref>). In this study, the overexpression of miR-654-5p promoted the expression of these fibrogenic genes in LX-2 cells, suggesting that miR-654-5p promotes the progression of LF.</p>
<p>Numerous studies have shown that miRNAs play key roles in HSC activation and LF. For example, miR-188-5p induces the activation and proliferation of HSCs, subsequently aggravating LF (<xref ref-type="bibr" rid="B26">Riaz et al., 2021</xref>). Meanwhile, miR-15b and miR-16 limit HSC proliferation and the fibrogenic response (<xref ref-type="bibr" rid="B23">Ma et al., 2021</xref>), whereas miR-34c promotes HSC activation and LF (<xref ref-type="bibr" rid="B16">Li et al., 2021c</xref>). Additionally, miR-494-3p attenuates HSC activation and induces apoptosis in LF (<xref ref-type="bibr" rid="B17">Li et al., 2021d</xref>). Moreover, miR-29a-3p suppresses HSC proliferation by targeting PIK3R3 (<xref ref-type="bibr" rid="B10">Fu et al., 2020</xref>).</p>
<p>Several studies have also investigated the effect of RXR&#x3b1; on HSC activation and the regulation of HSC function (<xref ref-type="bibr" rid="B25">Ohata et al., 1997</xref>; <xref ref-type="bibr" rid="B33">Vogel et al., 2000</xref>; <xref ref-type="bibr" rid="B11">He et al., 2020</xref>). RXR&#x3b1; inhibits HSC proliferation (<xref ref-type="bibr" rid="B28">Sharvit et al., 2013</xref>) and regulates apoptosis in certain cell types, including pancreatic beta cells (<xref ref-type="bibr" rid="B5">Chen et al., 2019</xref>) and mouse hippocampal cells (<xref ref-type="bibr" rid="B19">Litwa et al., 2016</xref>). Therefore, further investigation into RXR&#x3b1;-related regulation of HSCs may provide new perspectives for LF treatment.</p>
<p>Studies have shown that certain miRNAs participate in the LF process by targeting RXR&#x3b1;. For example, miR-34a expression is upregulated in the fibrotic liver, and miR-34a regulates the expression of downstream genes by targeting RXR&#x3b1; (<xref ref-type="bibr" rid="B24">Oda et al., 2014</xref>). Moreover, Ji et al. (<xref ref-type="bibr" rid="B13">Ji et al., 2009</xref>) found that miR-27a and 27b were upregulated in activated rat HSCs <italic>in vitro</italic>. Meanwhile, transfecting HSCs with anti-miR-27a and anti-miR-27b restored lipid droplets and inhibited the proliferation of HSCs by negatively regulating RXR&#x3b1;. To better understand the biological function of miR-654-5p in LF, we overexpressed miR-654-5p in LX-2 cells, and our <italic>in vitro</italic> results demonstrated that miR-654-5p directly targets RXR&#x3b1;. Moreover, overexpression of miR-654-5p induces HSCs to synthesize collagen by inhibiting RXR&#x3b1; during LF. We also observed a significant increase in miR-654-5p expression and downregulation of RXR&#x3b1; in the CCl<sub>4</sub>-induced fibrosis mouse model. Therefore, collectively these findings suggest that overexpression of miR-654-5p promotes LF progression in mice.</p>
<p>Several limitations were noted in this study. First, in addition to an miR-654-5p mimic, the miR-654-5p inhibitor was also used to treat LX-2 cells in this study. However, owing to the low transcription baseline of miR-654-5p in LX-2 cells, no significant effect was observed on its expression following the use of its inhibitor (this data is not shown in the paper). As an alternative, we overexpressed miR-654-5p in a murine model rather than inhibiting it. Second, &#x3b1;-SMA is a marker of myofibroblasts and is upregulated during HSC activation (myofibroblast-like cells) (<xref ref-type="bibr" rid="B20">Liu et al., 2019</xref>). However, in our study, the miR-654-5p mimic did not induce a significant change in the expression of &#x3b1;-SMA in LX-2 cells (data not shown). We speculate that the lack of detectable mRNA responses might be due to characteristics of LX-2, which is an immortalized HSC cell line and can be considered an activated phenotype of primary HSCs (<xref ref-type="bibr" rid="B37">Xu et al., 2005</xref>). In our study, although we controlled for the number of passages of LX-2 (&#x3c;10), &#x3b1;-SMA mRNA in LX-2 cells had a very high baseline level of &#x3b1;-SMA mRNA, which made it difficult to increase during further activation of LX-2 cells. Furthermore, no significant changes were detected in the expression of &#x3b1;-SMA in LX-2 cells after treatment with TGF-&#x3b2;1.</p>
<p>In conclusion, the findings of the study show that miR-654-5p induces activation and proliferation of HSCs, while inhibiting their apoptosis. In addition, miR-654-5p aggravates LF by, at least in part, blocking RXR&#x3b1;. Therefore, our findings may provide a new treatment strategy for LF.t</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by ethical committee of the First Hospital of Jilin University. The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>JN and XG conceived of and designed the study. HM performed the experiments, analyzed the data and drafted the manuscript. XW and XL participated in the experiments. CW assisted in sample collection.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>The study was sponsored by the National Natural Science Foundation of China (grant No. 81970519 and 81700534) and the WBE Liver Fibrosis Foundation (grant No. CFHPC2022002).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2022.841248/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcell.2022.841248/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material>
<label>Supplementary Figure S1</label>
<caption>
<p>MiR-654-5p and RXR&#x3b1; expression levels in culture-activated HSCs/quiescent HSCs according to previous RNA-sequencing data. Error bars represent mean &#xb1; SEM of experiments, &#x2a;&#x2a;p &#x3c; 0.01, and &#x2a;&#x2a;&#x2a;p &#x3c; 0.001.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure S2</label>
<caption>
<p>The targeting relationship between miR-654-5p and RXR&#x3b1; in human predicted by the Targetscan database.</p>
</caption>
</supplementary-material>
<supplementary-material>
<label>Supplementary Figure S3</label>
<caption>
<p>The targeting relationship between miR-654-5p and RXR&#x3b1; in mouse predicted by the Targetscan database.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Table2.XLSX" id="SM1" mimetype="application/XLSX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image3.JPEG" id="SM2" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image1.JPEG" id="SM3" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.JPEG" id="SM4" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdel-Bakky</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Helal</surname>
<given-names>G. K.</given-names>
</name>
<name>
<surname>El-Sayed</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Alhowail</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Alharbi</surname>
<given-names>K. S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Silencing of Tissue Factor by Antisense Deoxyoligonucleotide Mitigates Thioacetamide-Induced Liver Injury</article-title>. <source>Naunyn-schmiedeberg&#x27;s Arch. Pharmacol.</source> <volume>393</volume> (<issue>10</issue>), <fpage>1887</fpage>&#x2013;<lpage>1898</lpage>. <comment>PubMed PMID: 32430618</comment>. <pub-id pub-id-type="doi">10.1007/s00210-020-01896-0</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arthur</surname>
<given-names>M. J. P.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Fibrogenesis II. Metalloproteinases and Their Inhibitors in Liver Fibrosis</article-title>. <source>Am. J. Physiology-Gastrointestinal Liver Physiol.</source> <volume>279</volume> (<issue>2</issue>), <fpage>G245</fpage>&#x2013;<lpage>G249</lpage>. <comment>PubMed PMID: 10915630</comment>. <pub-id pub-id-type="doi">10.1152/ajpgi.2000.279.2.g245</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barcena-Varela</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Colyn</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fernandez-Barrena</surname>
<given-names>M. G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Epigenetic Mechanisms in Hepatic Stellate Cell Activation during Liver Fibrosis and Carcinogenesis</article-title>. <source>Ijms</source> <volume>20</volume> (<issue>10</issue>), <fpage>2507</fpage>. <comment>PubMed PMID: 31117267</comment>. <pub-id pub-id-type="doi">10.3390/ijms20102507</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bataller</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Liver Fibrosis</article-title>. <source>J. Clin. Invest.</source> <volume>115</volume> (<issue>2</issue>), <fpage>209</fpage>&#x2013;<lpage>218</lpage>. <comment>PubMed PMID: 15690074</comment>. <pub-id pub-id-type="doi">10.1172/jci24282</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z. X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Effects of RXR&#x3b1; on Proliferation and Apoptosis of Pancreatic Cancer Cells through TGF-&#x3b2;/Smad Signaling Pathway</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source> <volume>23</volume> (<issue>11</issue>), <fpage>4723</fpage>&#x2013;<lpage>4729</lpage>. <comment>PubMed PMID: 31210298</comment>. <pub-id pub-id-type="doi">10.26355/eurrev_201906_18053</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezhilarasan</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>MicroRNA Interplay between Hepatic Stellate Cell Quiescence and Activation</article-title>. <source>Eur. J. Pharmacol.</source> <volume>885</volume>, <fpage>173507</fpage>. <comment>PubMed PMID: 32858048</comment>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173507</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezhilarasan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sokal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Najimi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Hepatic Fibrosis: It Is Time to Go with Hepatic Stellate Cell-specific Therapeutic Targets</article-title>. <source>Hepatobiliary Pancreat. Dis. Int.</source> <volume>17</volume> (<issue>3</issue>), <fpage>192</fpage>&#x2013;<lpage>197</lpage>. <comment>PubMed PMID: 29709350</comment>. <pub-id pub-id-type="doi">10.1016/j.hbpd.2018.04.003</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease</article-title>. <source>Int. J. Biol. Sci.</source> <volume>17</volume> (<issue>7</issue>), <fpage>1851</fpage>&#x2013;<lpage>1863</lpage>. <comment>PubMed PMID: 33994867</comment>. <pub-id pub-id-type="doi">10.7150/ijbs.59588</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Mechanisms of Hepatic Fibrogenesis</article-title>. <source>Gastroenterology</source> <volume>134</volume> (<issue>6</issue>), <fpage>1655</fpage>&#x2013;<lpage>1669</lpage>. <comment>PubMed PMID: 18471545</comment>. <pub-id pub-id-type="doi">10.1053/j.gastro.2008.03.003</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>miR-29a-3p Suppresses Hepatic Fibrosis Pathogenesis by Modulating Hepatic Stellate Cell Proliferation via Targeting PIK3R3 Gene Expression</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>529</volume> (<issue>4</issue>), <fpage>922</fpage>&#x2013;<lpage>929</lpage>. <comment>PubMed PMID: 32819600</comment>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.06.102</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Expression of Hepatic Stellate Cell Activation-Related Genes in HBV-, HCV-, and Nonalcoholic Fatty Liver Disease-Associated Fibrosis</article-title>. <source>PLoS ONE</source> <volume>15</volume> (<issue>5</issue>), <fpage>e0233702</fpage>. <comment>PubMed PMID: 32442221</comment>. <pub-id pub-id-type="doi">10.1371/journal.pone.0233702</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>miR-654-5p Targets HAX-1 to Regulate the Malignancy Behaviors of Colorectal Cancer Cells</article-title>. <source>Biomed. Res. Int.</source> <volume>2020</volume>, <fpage>1</fpage>&#x2013;<lpage>6</lpage>. <comment>PubMed PMID: 32104694</comment>. <pub-id pub-id-type="doi">10.1155/2020/4914707</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Over-expressed microRNA-27a and 27b Influence Fat Accumulation and Cell Proliferation during Rat Hepatic Stellate Cell Activation</article-title>. <source>FEBS Lett.</source> <volume>583</volume> (<issue>4</issue>), <fpage>759</fpage>&#x2013;<lpage>766</lpage>. <comment>PubMed PMID: 19185571</comment>. <pub-id pub-id-type="doi">10.1016/j.febslet.2009.01.034</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Circular RNA Hsa_circ_0085131 Is Involved in Cisplatin&#x2010;resistance of Non&#x2010;small&#x2010;cell Lung Cancer Cells by Regulating Autophagy</article-title>. <source>Cell Biol Int</source> <volume>44</volume> (<issue>9</issue>), <fpage>1945</fpage>&#x2013;<lpage>1956</lpage>. <comment>PubMed PMID: 32449799</comment>. <pub-id pub-id-type="doi">10.1002/cbin.11401</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>J. L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Role of the Retinoid Receptor, RAR/RXR Heterodimer, in Liver Physiology</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Basis Dis.</source> <volume>1867</volume> (<issue>5</issue>), <fpage>166085</fpage>. <comment>PubMed PMID: 33497820</comment>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2021.166085</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>MiR-34c Promotes Hepatic Stellate Cell Activation and Liver Fibrogenesis by Suppressing ACSL1 Expression</article-title>. <source>Int. J. Med. Sci.</source> <volume>18</volume> (<issue>3</issue>), <fpage>615</fpage>&#x2013;<lpage>625</lpage>. <comment>PubMed PMID: 33437196</comment>. <pub-id pub-id-type="doi">10.7150/ijms.51589</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>MicroRNA-494-3p Prevents Liver Fibrosis and Attenuates Hepatic Stellate Cell Activation by Inhibiting Proliferation and Inducing Apoptosis through Targeting TRAF3</article-title>. <source>Ann. Hepatol.</source> <volume>23</volume>, <fpage>100305</fpage>. <comment>PubMed PMID: 33434689</comment>. <pub-id pub-id-type="doi">10.1016/j.aohep.2021.100305</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>LINC00261 Relieves the Progression of Sepsis-Induced Acute Kidney Injury by Inhibiting NF-&#x39a;b Activation through Targeting the miR-654-5p/SOCS3 axis</article-title>. <source>J. Bioenerg. Biomembr</source> <volume>53</volume> (<issue>2</issue>), <fpage>129</fpage>&#x2013;<lpage>137</lpage>. <comment>PubMed PMID: 33481135</comment>. <pub-id pub-id-type="doi">10.1007/s10863-021-09874-8</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Litwa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rzemieniec</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wnuk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lason</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Krzeptowski</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kajta</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>RXR&#x3b1;, PXR and CAR Xenobiotic Receptors Mediate the Apoptotic and Neurotoxic Actions of Nonylphenol in Mouse Hippocampal Cells</article-title>. <source>J. Steroid Biochem. Mol. Biol.</source> <volume>156</volume>, <fpage>43</fpage>&#x2013;<lpage>52</lpage>. <comment>PubMed PMID: 26643981</comment>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2015.11.018</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Koroleva</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Z. G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Myofibroblast-specific YY1 Promotes Liver Fibrosis</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>514</volume> (<issue>3</issue>), <fpage>913</fpage>&#x2013;<lpage>918</lpage>. <comment>PubMed PMID: 31084931</comment>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2019.05.004</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma through Ras/MAPK Signaling</article-title>. <source>DNA Cel Biol.</source> <volume>37</volume> (<issue>4</issue>), <fpage>381</fpage>&#x2013;<lpage>388</lpage>. <comment>PubMed PMID: 29364705</comment>. <pub-id pub-id-type="doi">10.1089/dna.2017.4095</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Interference with circRNA DOCK1 Inhibits Hepatocellular Carcinoma Cell Proliferation, Invasion and Migration by Regulating the miR-654-5p/SMAD2 axis</article-title>. <source>Mol. Med. Rep.</source> <volume>24</volume> (<issue>2</issue>). <comment>PubMed PMID: 34184075</comment>. <pub-id pub-id-type="doi">10.3892/mmr.2021.12247</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>MiR-15b and miR-16 Suppress TGF-&#x392;1-Induced Proliferation and Fibrogenesis by Regulating LOXL1 in Hepatic Stellate Cells</article-title>. <source>Life Sci.</source> <volume>270</volume>, <fpage>119144</fpage>. <comment>PubMed PMID: 33545201</comment>. <pub-id pub-id-type="doi">10.1016/j.lfs.2021.119144</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsuneyama</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takamiya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fukami</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Retinoid X Receptor &#x3b1; in Human Liver Is Regulated by miR-34a</article-title>. <source>Biochem. Pharmacol.</source> <volume>90</volume> (<issue>2</issue>), <fpage>c</fpage>&#x2013;<lpage>187</lpage>. <comment>PubMed PMID: 24832862</comment>. <pub-id pub-id-type="doi">10.1016/j.bcp.2014.05.002</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Satre</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsukamoto</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Diminished Retinoic Acid Signaling in Hepatic Stellate Cells in Cholestatic Liver Fibrosis</article-title>. <source>Am. J. Physiol.</source> <volume>272</volume> (<issue>3 Pt 1</issue>), <fpage>G589</fpage>&#x2013;<lpage>G596</lpage>. <comment>PubMed PMID: 9124579</comment>. <pub-id pub-id-type="doi">10.1152/ajpgi.1997.272.3.G589</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riaz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Osoro</surname>
<given-names>E. K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Inhibition of miR&#x2010;188&#x2010;5p Alleviates Hepatic Fibrosis by Significantly Reducing the Activation and Proliferation of HSCs through PTEN/PI3K/AKT Pathway</article-title>. <source>J. Cel Mol Med</source> <volume>25</volume> (<issue>8</issue>), <fpage>4073</fpage>&#x2013;<lpage>4087</lpage>. <comment>PubMed PMID: 33689215</comment>. <pub-id pub-id-type="doi">10.1111/jcmm.16376</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roeb</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Matrix Metalloproteinases and Liver Fibrosis (Translational Aspects)</article-title>. <source>Matrix Biol.</source> <volume>68-69</volume>, <fpage>463</fpage>&#x2013;<lpage>473</lpage>. <comment>PubMed PMID: 29289644</comment>. <pub-id pub-id-type="doi">10.1016/j.matbio.2017.12.012</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharvit</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Abramovitch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Reif</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bruck</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Amplified Inhibition of Stellate Cell Activation Pathways by PPAR-&#x3b3;, RAR and RXR Agonists</article-title>. <source>PLoS ONE</source> <volume>8</volume> (<issue>10</issue>), <fpage>e76541</fpage>. <comment>PubMed PMID: 24098526</comment>. <pub-id pub-id-type="doi">10.1371/journal.pone.0076541</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S. C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>MiR-654-5p Attenuates Breast Cancer Progression by Targeting EPSTI1</article-title>. <source>Am. J. Cancer Res.</source> <volume>6</volume> (<issue>2</issue>), <fpage>522</fpage>&#x2013;<lpage>532</lpage>. <comment>PubMed PMID: 27186421</comment>. </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis</article-title>. <source>Biomed. Res. Int.</source> <volume>2020</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. <comment>PubMed PMID: 32733951</comment>. <pub-id pub-id-type="doi">10.1155/2020/7269150</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>MicroRNAs in Common Diseases and Potential Therapeutic Applications</article-title>. <source>Clin. Exp. Pharmacol. Physiol.</source> <volume>37</volume> (<issue>1</issue>), <fpage>102</fpage>&#x2013;<lpage>107</lpage>. <comment>PubMed PMID: 19671070</comment>. <pub-id pub-id-type="doi">10.1111/j.1440-1681.2009.05269.x</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuchida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Mechanisms of Hepatic Stellate Cell Activation</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>14</volume> (<issue>7</issue>), <fpage>397</fpage>&#x2013;<lpage>411</lpage>. <comment>PubMed PMID: 28487545</comment>. <pub-id pub-id-type="doi">10.1038/nrgastro.2017.38</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Piantedosi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lalazar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rockey</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>S. L.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>An Immortalized Rat Liver Stellate Cell Line (HSC-T6): a New Cell Model for the Study of Retinoid Metabolism <italic>In Vitro</italic>
</article-title>. <source>J. Lipid Res.</source> <volume>41</volume> (<issue>6</issue>), <fpage>882</fpage>&#x2013;<lpage>893</lpage>. <comment>PubMed PMID: 10828080</comment>. <pub-id pub-id-type="doi">10.1016/s0022-2275(20)32030-7</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>miR-654-5p I-nhibits A-utophagy by T-argeting ATG7 via mTOR S-ignaling in I-ntervertebral D-isc D-egeneration</article-title>. <source>Mol. Med. Rep.</source> <volume>23</volume> (<issue>6</issue>), <fpage>12083</fpage>. <comment>PubMed PMID: 33846806</comment>. <pub-id pub-id-type="doi">10.3892/mmr.2021.12083</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Effect of the Regulation of Retinoid X Receptor-&#x3b1; Gene Expression on Rat Hepatic Fibrosis</article-title>. <source>Hepatol. Res.</source> <volume>41</volume> (<issue>5</issue>), <fpage>475</fpage>&#x2013;<lpage>483</lpage>. <comment>PubMed PMID: 21518404</comment>. <pub-id pub-id-type="doi">10.1111/j.1872-034X.2011.00794.x</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Werner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Driftmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kleinehr</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Math&#xe9;</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Treckmann</surname>
<given-names>J.-W.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>All-In-One: Advanced Preparation of Human Parenchymal and Non-parenchymal Liver Cells</article-title>. <source>PLoS ONE</source> <volume>10</volume> (<issue>9</issue>), <fpage>e0138655</fpage>. <comment>PubMed PMID: 26407160</comment>. <pub-id pub-id-type="doi">10.1371/journal.pone.0138655</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>A. Y.</given-names>
</name>
<name>
<surname>Albanis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Arthur</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>O&#x27;Byrne</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Blaner</surname>
<given-names>W. S.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Human Hepatic Stellate Cell Lines, LX-1 and LX-2: New Tools for Analysis of Hepatic Fibrosis</article-title>. <source>Gut</source> <volume>54</volume> (<issue>1</issue>), <fpage>142</fpage>&#x2013;<lpage>151</lpage>. <comment>PubMed PMID: 15591520</comment>. <pub-id pub-id-type="doi">10.1136/gut.2004.042127</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X. Z.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>MiR-654-5p Regulated Cell Progression and Tumor Growth through Targeting SIRT6 in Osteosarcoma</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source> <volume>24</volume> (<issue>7</issue>), <fpage>3517</fpage>&#x2013;<lpage>3525</lpage>. <comment>PubMed PMID: 32329825</comment>. <pub-id pub-id-type="doi">10.26355/eurrev_202004_20811</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Furuta</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sabit</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tamai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jiapaer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Gelsolin Inhibits Malignant Phenotype of Glioblastoma and Is Regulated by miR&#x2010;654&#x2010;5p and miR&#x2010;450b&#x2010;5p</article-title>. <source>Cancer Sci.</source> <volume>111</volume> (<issue>7</issue>), <fpage>2413</fpage>&#x2013;<lpage>2422</lpage>. <comment>PubMed PMID: 32324311</comment>. <pub-id pub-id-type="doi">10.1111/cas.14429</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>